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Abstract
Bradykinin (BK), generated from high-molecular-weight kininogen (HK) is the major mediator of swelling attacks in
hereditary angioedema (HAE), a disease associated with C1-inhibitor deficiency. Plasma kallikrein, activated by factor XIIa, is
responsible for most of HK cleavage. However other proteases, which activate during episodes of angioedema, might also
contribute to BK production. The lectin pathway of the complement system activates after infection and oxidative stress on
endothelial cells generating active serine proteases: MASP-1 and MASP-2. Our aim was to study whether activated MASPs
are able to digest HK to release BK. Initially we were trying to find potential new substrates of MASP-1 in human plasma by
differential gel electrophoresis, and we identified kininogen cleavage products by this proteomic approach. As a control,
MASP-2 was included in the study in addition to MASP-1 and kallikrein. The proteolytic cleavage of HK by MASPs was
followed by SDS-PAGE, and BK release was detected by HPLC. We showed that MASP-1 was able to cleave HK resulting in BK
production. MASP-2 could also cleave HK but could not release BK. The cleavage pattern of MASPs is similar but not strictly
identical to that of kallikrein. The catalytic efficiency of HK cleavage by a recombinant version of MASP-1 and MASP-2 was
about 4.0610
2 and 2.7610
2 M
21s
21, respectively. C1-inhibitor, the major inhibitor of factor XIIa and kallikrein, also
prevented the cleavage of HK by MASPs. In all, a new factor XII- and kallikrein-independent mechanism of bradykinin
production by MASP-1 was demonstrated, which may contribute to the pro-inflammatory effect of the lectin pathway of
complement and to the elevated bradykinin levels in HAE patients.
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Introduction
Bradykinin (BK) is a potent proinflammatory peptide that is
released from its precursors high-molecular-weight kininogen
(HK) and low-molecular-weight kininogen (LK) by means of
limited proteolysis. Plasma kallikrein and tissue kallikrein are the
serine proteases that are responsible for BK generation [1,2]. The
release of BK triggers inflammatory reactions via activating
endothelial cells resulting in vasodilatation, increased vascular
permeability, and production of second-generation mediators such
as nitric oxide, prostaglandins and leukotrienes [3]. In patients
with hereditary angioedema (HAE) the uncontrolled release of BK
leads to recurrent tissue swelling that can be lethal if it occurs in
the larynx. HAE can be the consequence of the deficiency of
functional C1-inhibitor which is the primary inhibitor of the
complement and the contact activation systems [4–6].
The contact activation system is the major source of BK
production in plasma. It is a proteolytic cascade system in the
blood that can be activated by incubation of plasma with negatively
charged artificial surfaces (e.g. glass, kaolin) or with certain
biological macromolecules (e.g. LPS, amyloid b protein) bound to
the surface of different cell types, including endothelial cells,
platelets, and polymorphonuclear neutrophils [7]. The first step of
contact activation is the autoactivation factor XII. Activated factor
XII (factor XIIa) then cleaves and activates factor XI and
prekallikrein. Activation of factor XI initiates the intrinsic pathway
of coagulation while activation of prekallikrein results in BK
production. Most of the prekallikrein (about 85%) can be found in
equimolar complex with HK which can bind to cell surfaces [1,2,8].
In this way contact system activation results in immediate BK
release on the cells, to which its components are bound.
Another major proteolytic cascade system in the blood is the
complement system which is an important component of the
innate immune system. Activation of the complement system
results in the elimination of pathogens and altered self structures
(e.g. apoptotic, necrotic cells), and triggers inflammatory reactions
[9]. The complement system can be activated through three
different activation routes: the classical, the lectin and the
alternative pathways [10]. In the case of the lectin pathway
pattern recognition molecules (mannose-binding lectin (MBL),
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different danger signals arisen from invading pathogens or altered
self structures. MBL and ficolins form multimolecular complexes
with serine proteases (MBL-associated serine proteases=MASPs)
that autoactivate upon the recognition molecules bind to the
activator structures [11]. One of the MASPs, MASP-2, is able to
initiate the complement cascade, since it can cleave C2 and C4,
the components of the C3-convertase enzyme complex. MASP-1
however cannot induce C3-convertase formation alone, since it
cannot cleave C4. We have shown previously that MASP-1 can
exert proinflammatory activities since it can cleave fibrinogen
releasing fibrinopeptide A and B [12], and it can stimulate
endothelial cells by cleaving the protease-activated receptor 4
(PAR4) [13]. MASP-1 has also been implicated in clot formation
both in vitro [14] and in vivo [15].
In the present work we demonstrate that MASP-1 is capable of
digesting HK to release BK. This phenomenon can contribute to
the initiation of inflammatory reaction during complement
activation establishing a stronger innate immune response.
MASP-2 can also cleave HK, but cannot release BK. Since C1-
inhibitor inhibits the activity of both MASPs [16,17], it might be
possible that the BK-producing activity of MASP-1 can also
contribute to the elevated BK level in the case of HAE.
Materials and Methods
Materials
Recombinant human MASP-1 and MASP-2 catalytic frag-
ments, rMASP-1 and rMASP-2, were prepared as described
previously [16,18,19]. These recombinant fragments are com-
posed of the last 3 domains including the catalytic domain, but
lack the first 3 domains responsible for the interaction with MBL
and ficolins. The concentrations of rMASP-1 and rMASP-2 were
calculated using the extinction coefficients e=1.54, and
1.88 ml mg
21 cm
21, and a molecular weights of 45.5, and
43.3 kDa, respectively [18]. Human HK was purchased from
Calbiochem (Darmstadt, Germany), or Innovative Research
(Novi, MI): both of them were about the same good quality.
Human plasma kallikrein (referred to as kallikrein) and human
plasma prekallikrein (referred to as prekallikrein) were from
Innovative Research (Novi, MI). The molar concentration of
kallikrein was calculated based on the product label and a
molecular weight of 88 kDa. Human LK was from Sigma (cat.
no. K3628 St Louis, MO), however 2 out of 3 batches were
already cleaved preventing its use for detailed LK cleavage studies.
The selective peptide substrate for MASP-1, LPAPR-AMC, was
custom-ordered from Bio Basic (Toronto, Canada). Human C1-
inhibitor (Berinert P) was from CSL Behring (King of Prussia, PA).
The concentration of C1-inhibitor was calculated using the
extinction coefficient e=0.382 ml mg
21 cm
21, and a molecular
weight of 71 kDa [20]. All proteins were dissolved in, or buffer-
exchanged to HEPES-buffered saline (HBS) buffer (140 mM
NaCl, 50 mM HEPES, 0.1 mM EDTA, pH 7.4). BK-acetate was
obtained from Sigma (St Louis, MO).
Differential gel electrophoresis (DIGE)
Human plasma was depleted of 7 abundant components (serum
albumin, transferrin, haptoglobin, IgA, IgG, anti-trypsin and
fibrinogen) using a Hu-PL-7 multiple affinity removal column
(Agilent, Wilmington, DE) according to the instructions of the
manufacturer. Total protein concentration in the pooled depleted
plasma was determined using the BCA assay (Pierce, Rockford,
IL). Depleted plasma at a final plasma protein concentration of
570 mg/ml was incubated in the presence and absence of 10 mg/
ml rMASP-1 at 37uC for 1 hour in Tris-buffered saline (TBS)
buffer (150 mM NaCl, 20 mM Tris, 0.1 mM EDTA, pH 7.4).
Another sample was made with 60 mg/ml C1-inhibitor present in
addition to rMASP-1. When the incubation was complete salts
and lipids were removed by the method of Santos-Gonza ´lez et al.
[21]. Finally the dry protein pellets were dissolved in lysis buffer
Figure 1. Cleavage of HK by rMASP-1, rMASP-2 and kallikrein,
and the effect of C1-inhibitor. (A) Kininogen cleavage products
identified by 2D-DIGE. Depleted human plasma was incubated alone or
in the presence of rMASP-1 in TBS buffer (see Methods). Green spots
represent products present in the rMASP-1 treated sample only.
Approximate isoelectric points are indicated on the top and molecular
weights on the side. (B) HK (200 mg/ml) was incubated with kallikrein
(0.5 mg/ml), rMASP-1 (25 mg/ml), or rMASP-2 (25 mg/ml) in HBS buffer
(see Methods) at 37uC. Samples were taken periodically (time in minutes
indicated), and 15 ml aliquots were run on SDS-PA gels under reducing
conditions. (C) C1-inhibitor (150 mg/ml) prevented cleavage of HK when
added to a set of samples prepared as above.
doi:10.1371/journal.pone.0020036.g001
MASP-1 Cleaves Kininogen
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Protocol of sample preparation for DIGE was used as we
described previously [22]. Briefly, 50 mg amount of plasma
proteins (the untreated, rMASP-1-treated, and the C1-inhibitor
+ rMASP-1 treated samples, respectively) were labeled with
CyDye DIGE Fluor Minimal Labeling Kit (GE Healthcare, Little
Chalfont, UK) at a ratio of 400 pmol/50 mg protein according to
the instructions. The three differently marked samples were
multiplexed and resolved in the same gel. Six gels were prepared.
Following electrophoresis, gels were scanned in a Typhoon Trio+
laser scanner (GE Healthcare) using appropriate lasers and filters
with the photomultiplier tube biased at 580 V. Images in different
channels were overlaid using selected colors and differences were
visualized using Image Quant software (GE Healthcare). Differ-
ential protein analysis was performed using DeCyder software
package 6.0 (GE Healthcare). Spots, the intensity of which
appeared or increased on rMASP-1 treatment, and disappeared or
Figure 2. HPLC analysis of HK samples treated with kallikrein or rMASP-1. Samples were run on a Source5 RPC ST 4.6/150 column as
described in the Methods. The vertical dotted line indicates the elution position of BK. Dashed line is the percentage of the eluent (%B). Synthetic BK
(500 ng) served as a control. BK released by rMASP-1 was confirmed by MS.
doi:10.1371/journal.pone.0020036.g002
Figure 3. Simplified fragmentation profile of HK produced by the action of kallikrein and rMASP-1. Only the fragments that explain the
patterns observed on SDS-PAGE are indicated, however it should be noted that the release of BK requires two cleavage steps, which are combined on
this figure.
doi:10.1371/journal.pone.0020036.g003
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1 cleavage products.
For protein identification 800 mg of rMASP-1-treated (as above)
plasma proteins were run on the 2D gel electrophoresis system as
described above, but omitting the labeling step. Gels were stained
with Coomassie Brilliant Blue G (Sigma, St Louis, MO), and spots
of identified MASP-1 cleavage products were excised from the gel.
Protein identification was carried out in the Proteomics Central
Facility, University of Szeged (Szeged, Hungary) by MALDI-TOF
mass spectrometric analysis of the peptides obtained by tryptic
digestion of soaked gel slices [22].
HPLC and MS
HK (200 mg/ml) was incubated with 0.5 mg/ml kallikrein,
25 mg/ml rMASP-1, 25 mg/ml rMASP-2, or rMASP-1 and
rMASP-2 combined (both 25 mg/ml) in HBS (140 mM NaCl,
50 mM HEPES, 0.1 mM EDTA, pH 7.4) buffer in a final volume
of 500 ml. After 3 hours at 37uC samples were mixed with 250 ml
of 1% TFA 2% acetonitrile to stop the reaction. 500 ml of the
samples prepared as above (corresponding to 333 ml of the original
mixture) were run on a Source 5RPC ST 4.6/150 (GE
Healthcare, Uppsala, Sweden) column, and eluted with a 2–
80% acetonitrile gradient in 0.1% TFA. Synthetic BK-acetate
served as a control. The amount of BK released was estimated by
comparing the area under the curve (AUC) of the BK peak to that
of a known amount of pure BK applied. Electrospray ionization
mass spectrometric analysis was carried out by directly injecting
the presumed BK-containing fractions into a HP-1100 series
HPLC-ESI-MS system (Hewlett-Packard, San Diego, CA, USA).
The flow rate of 10 mM ammonium-formiate buffer was 0.2 ml/
min. The drying nitrogen gas flow rate was 10 l/min at 300uCa ta
pressure of 30 PSI and the capillary voltage was 4000 V. Total ion
current (TIC) chromatogram was obtained in positive ion mode by
scanning in the 300–2000 mass/charge range. The mass
information was evaluated using Agilent ChemStation software.
SDS-PAGE, densitometry and regression analysis
HK or LK (200 mg/ml) was incubated with 0.5 mg/ml
kallikrein, 25–50 mg/ml rMASP-1, or 25–50 mg/ml rMASP-2 in
HBS buffer at 37uC for 0–900 minutes as required. Samples were
run on standard 12.5% SDS-PA gels [23] under reducing
conditions, except that twice the normal concentration of Tris
was used in the separating gel. The heavy and light chains of HK
are separated under these conditions. Gels were scanned using the
BioRad (Hercules, CA) Gel Doc XR system. Densitometric
analysis was done with the Quantity One 4.6.3 software (BioRad,
Hercules, CA) in volume analysis mode. A good approximation of
the catalytic constants was obtained by fitting the intensity (I) of
the intact HK band using the I=Io6e
2kobs6t equation, where
kobs=[E T]6kcat/KM, and [ET] is the total enzyme concentration.
MBL-MASP complex: preparation and HK cleavage
The complexes of MBL and MASPs were prepared essentially
by the method described by Tan et al. [24]. Briefly: plasma was
thawed, precipitated with PEG3350, then the dissolved pellet was
loaded to mannose-sepharose (Sigma, St Louis, MO) in TBS-Ca
buffer (150 mM NaCl, 50 mM Tris, pH 7.8, 20 mM CaCl2,
0.05% Tween-20), eluted with the same buffer containing 10 mM
EDTA instead of CaCl2. After adding CaCl2 to 40 mM final
concentration the partially purified complex was loaded to
maltose-sepharose (Sigma, St Louis, MO), and eluted with TBS-
Ca containing 100 mM N-acetyl-glucosamine. The activity of
MASP-1 in the preparation was determined using the LPAPR-
AMC substrate as described [13]. Comparing the activity of
plasma MASP-1 to the activity of known concentration of rMASP-
1 allowed us to estimate the concentration of MASP-1 in the
MBL-MASP preparation. 1.5 ml of 2 mg/ml HK (200 mg/ml
final) was added to 13.5 ml aliquots of MBL-MASP complexes and
incubated at 37uC for 0–6 hours. The samples were analyzed by
reducing SDS-PAGE. Densitometry and regression was done as
described in the previous section.
Results
MASP-1 and MASP-2 can cleave HK
The initial hit that MASP-1 is able to cleave kininogen(s) came
from 2D-DIGE analysis of depleted human plasma treated with a
recombinant MASP-1 catalytic fragment (rMASP-1) in a search to
find novel MASP-1 substrates. Actually a ‘‘train’’ of kininogen
cleavage products was the most pronounced difference on the 2D
gel of the rMASP-1-treated and the untreated plasma sample
(Figure 1A). Therefore we undertook to examine the effect of
rMASP-1 on isolated HK. As controls plasma kallikrein and a
similar recombinant version of MASP-2, named rMASP-2, were
Figure 4. Kinetics of HK cleavage. HK (200 mg/ml) was incubated
with (A) kallikrein (0.5 mg/ml), (B) rMASP-1 (50 mg/ml), or (C) rMASP-2
(30 mg/ml) in HBS buffer (see Methods) at 37uC. Samples were taken
periodically (time in minutes indicated), and 15 ml aliquots were run on
SDS-PA gels under reducing conditions. The kinetic constants,
determined by densitometry of the HK band followed by non-linear
regression analysis, are found in Table 1.
doi:10.1371/journal.pone.0020036.g004
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although slower than kallikrein. Interestingly rMASP-2 was also
able to cleave HK at a somewhat slower, but comparable rate as
rMASP-1 (Figure 1B).
C1-inhibitor is known to inhibit all 3 proteases [1,4,16,17]. In
order to check weather C1-inhibitor is able to prevent cleavage of
HK by rMASP-1, rMASP-2 or kallikrein, a molar excess of C1-
inhibitor (compared to the protease) was added to HK before the
addition of the protease to a set of samples. As expected
(Figure 1C) degradation of HK was completely prevented in all
three cases by the addition of excess C1-inhibitor.
BK release
The release of BK was monitored by reverse-phase HPLC. The
chromatograms on Figure 2 illustrate the cleavage products
obtained by prolonged incubation of HK in the presence of
kallikrein, or rMASP-1. In both cases a peak with the same elution
time as synthetic BK could be observed. Subsequent MS analysis
revealed that the molecular weight of the species in the peak was
identical with that of BK. Consequently cleavage of HK by
rMASP-1 results in BK release, similar to kallikrein.
It should be noted that according to our calculations MASP-1
produced approximately 25–30% of the potentially releasable BK
from HK, whereas kallikrein released about 90–100% during the
time course of the experiment.
In the case of rMASP-2 we could not detect a BK peak by
HPLC (data not shown), therefore it cannot produce detectable
amounts of BK from HK on its own in spite of the fact that it
cleaves HK seemingly very much alike kallikrein (Figure 1B). It is
likely that the BK segment remains attached to the H (or the L)
chain upon HK cleavage by MASP-2.
All proteases can cleave HK at other positions as well, since
besides the BK peak, peaks of other unidentified peptides are
present in the chromatograms (Figure 2). A likely source of these
peptides is the L1 segment (Figure 3) of the light (L) chain, since
the disulfide bonded heavy (H) and L2 chains are known to form a
stable end product [25,26] in the case of kallikrein-treated HK,
and the same can be observed in the case of rMASP-1 and
rMASP-2, too.
Cleavage pattern of HK
As it can be observed on Figure 1B (and also on Figure 4) the
cleavage pattern of HK by rMASP-1 is somewhat different from
that of by kallikrein, whereas rMASP-2 digests HK in a way
seemingly similar to kallikrein. Figure 3 depicts the likely cleavage
pattern of kallikrein and MASP-1. In the case of kallikrein, HK is
converted to a heavy (H) and a light (L) chain first [1,26] releasing
BK form the H chain shortly afterwards. Since BK release requires
two cleavage steps its production is somewhat delayed [27]
compared to the initial cleavage of HK. A third slower cleavage
occurs within the L chain between R437 and K438 [26] producing
the end product of HK degradation. It seems like that in the case
of rMASP-1 the fastest cleavage occurs at or near this site because
only a small amount of L chain is produced, and a fragment larger
that the H chain appears on the reduced SDS-PA gels. In the case
of rMASP-2 the cleavage pattern is similar to the one by kallikrein
(Figure 3), except that BK remains attached to the H (or L) chain.
Kinetics of HK cleavage
HK was incubated in the presence of kallikrein, rMASP-1, or
rMASP-2 at 37uC, samples were taken periodically, the reaction
was stopped by adding reducing SDS-PAGE sample buffer, and
the samples were analyzed by SDS-PAGE (Figure 4). The kinetic
constants (kcat/KM) were determined by densitometric analysis of
the intact HK bands followed by non-linear regression analysis.
rMASP-1 cleaved HK at a rate about 300–400-fold slower,
whereas rMASP-2 cleaved it about 500–600-fold slower than
kallikrein (Table 1). These values represent the overall initial (i.e.
at any site) cleavage rates and BK release is somewhat delayed
compared to these values as explained before. In plasma MASP-1
and MASP-2 are found associated with MBL and ficolins, and
their activation is linked [28], hence in plasma the effect of the two
enzymes might be additive in term of HK cleavage. We tested the
possibility that MASP-2 can also influence the BK production. We
found however that the presence of active MASP-2 did not change
the amount of BK released by MASP-1 (data not shown).
Figure 5. LK cleavage by rMASP-1. LK (200 mg/ml) was incubated in
HBS buffer (see Methods) at 37uC (time in minutes indicated) in the
presence of 50 mg/ml rMASP-1. 10 ml samples per lane were analyzed
by reducing SDS-PAGE. Densitometric analysis revealed that the
cleavage rate of rMASP-1 on LK is about 5 times lower than that on HK.
doi:10.1371/journal.pone.0020036.g005
Table 1. The observed rate constants (kobs) and the calculated catalytic efficiencies (kcat/KM) of HK cleavage by kallikrein and
MASPs.
protease enzyme conc. [ET]k obs (s
21)k cat/KM (M
21 s
21) relative activity
kallikrein 5.7610
29 M 8.660.8610
24 1.560.1610
5 1
rMASP-1 1.1610
26 M4 . 5 60.2610
24 4.060.2610
2 1/375
rMASP-2 0.7610
26 M 1.960.1610
24 2.760.2610
2 1/555
doi:10.1371/journal.pone.0020036.t001
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Our preliminary experiments show that LK is also cleaved by
rMASP-1 (Figure 5). The cleavage rate of LK is about 5-times
lower (kcat/KM,80 M
21s
21) than that of HK, hence this process
is likely to be less relevant. Kallikrein can also cleave LK, however
this process is thought to be less significant physiologically [1,29]
than HK cleavage.
rMASP-1 does not activate plasma prekallikrein
The HK preparations used can potentially contain contami-
nating proteases. To test for this possibility HK was incubated in
the reaction buffer, and it was not significantly degraded in
3 hours at 37uC( Figure 1B). Another possibility is that HK may
be contaminated by a small amount of prekallikrein, and if
rMASP-1 is able to activate prekallikrein, then cleavage of HK
would be due to the kallikrein formed by the action of rMASP-1
and not to rMASP-1 itself. In order to exclude this possibility we
examined the action of rMASP-1 on prekallikrein. As shown on
Figure 6 prekallikrein is not activated by rMASP-1 during
prolonged incubation at 37uC. rMASP-2 also did not cause any
significant prekallikrein activation (data not shown), whereas
kallikrein resulted in slow activation of prekallikrein as expected
[30] (Figure 6). It was reported earlier that Heat Shock Protein
90 catalyzes the activation of prekallikrein but only if prekallikrein
is bound to HK [31]. We tested whether MASPs are able to
activate prekallikrein in the presence of excess HK, however we
could not detect any activation of prekallikrein (data not shown).
The complexes of MBL and MASPs also cleave HK
Physiologically MASP-1 and MASP-2 are in complexes with
MBL and ficolins. We prepared partially purified MBL-MASPs
complexes. Adding HK to the MBL-MASPs complexes resulted in
cleavage of HK in a similar fashion as that of by rMASP-1 and
rMASP-2. The cleavage occurs in the presence and absence of
Ca
2+ with similar efficiency (data not shown). The isolated
complexes presented in Figure 7 contained about 60–100 nM
MASP-1 determined from the activity measured on a selective
MASP-1 substrate [13]. The estimated kcat/KM is in the range of
1000–3000 M
21s
21, which is significantly higher than the value
determined for rMASP-1. The cleavage pattern suggests that
MASP-2 may also play a role. The MASP-2 concentration in the
preparation was not determined, although it is expected to be
much less than that of MASP-1 because of its significantly lower
serum concentration (MASP-2=0.5 mg/ml vs. MASP-1=6 mg/
ml) [32,33]. Further studies would be necessary to measure the
accurate cleavage rates on separate MBL-MASP-1 and MBL-
MASP-2 complexes, and on isolated plasma MASP-1 and MASP-
2 however, the preparation of these is not well established.
Discussion
The lectin pathway of the complement serves as a first line of
defense against invading pathogens and it also initiates of
clearance of altered host cells. MBL and ficolins (H-, L- and M
ficolin) are soluble pattern recognition receptors that form
multimolecular complexes with MASPs. MASPs are present as
zymogens until the recognition molecules bind to the target
structure. Upon such binding the zymogen serine proteases
autoactivate and initiate the effector phase of the complement
cascade [11]. Up to now three MASPs are known: MASP-1,
MASP-2 and MASP-3. The physiological role of MASP-2 is well-
known: it can initiate the complement cascade by cleaving C2 and
C4 complement components. The role of MASP-3 is still elusive.
MASP-1 is an active serum protease and several potential
physiological substrates have been proposed [11–13,16,18].
MASP-1 can cleave complement component C2, but cannot
cleave C4 efficiently, therefore it is unable to initiate the
complement cascade alone. It was shown however, that MASP-1
can augment the activity of MASP-2 either by activating zymogen
MASP-2 or facilitating C3-convertase formation due to its C2
digesting activity [28,34,35]. We also showed that MASP-1 can
cleave some typical thrombin substrates such as fibrinogen, factor
XIII and PAR4 [12,13]. The crystal structure of MASP-1 [16]
suggests that it has more relaxed substrate specificity than related
complement proteases having only one or two natural substrates
(e. g. C1r, C1s, MASP-2).
In order to identify further potential physiological substrates for
MASP-1 in plasma we used a proteomic approach. We incubated
human plasma with active recombinant MASP-1 and analyzed the
results by differential gel electrophoresis (DIGE). One of the most
clear-cut hits was a set of kininogen cleavage products. This result
prompted us to analyze the digestion of HK by MASP-1 in detail.
We demonstrated that both MASP-1 and MASP-2 are able to
cleave HK analogously to plasma kallikrein. HK degradation by
MASP-1 also produced BK, while MASP-2 did not release BK.
Cleavage of a kallikrein substrate by MASP-1 is supported by the
structural data. Overlaying the structures [16,36], the substrate
binding groove of MASP-1 (PDB code 3GOV) seems to be
compatible with that of kallikrein (PDB code 2ANY), but not the
other way around, i.e. the substrates of kallikrein can probably fit
into MASP-1, but the some substrates of MASP-1 probably collide
with residue Lys575 (precursor numbering) of kallikrein (data not
shown).
In our work we discovered a novel factor XII- and kallikrein-
independent mechanism of BK formation. MASP-1 and MASP-2
can be activated during infection or stressful conditions. It was
demonstrated previously that MBL can bind to endothelial cells
following periods of oxidative stress and initiate the complement
cascade [37]. It means that activation of MASPs and MASP-1-
mediated HK cleavage can take place on the surface of the
endothelial cells where the local concentration of MASPs can be
much higher than in serum. This phenomenon can be an
Figure 6. rMASP-1 does not activate prekallikrein. Prekallikrein
(100 mg/ml) was incubated in HBS buffer (see Methods) at 37uC (time in
minutes indicated) in the presence of 5 mg/ml kallikrein or rMASP-1.
10 ml samples per lane were analyzed by reducing SDS-PAGE. The
contrast was somewhat enhanced for the better visibility of faint bands.
doi:10.1371/journal.pone.0020036.g006
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ment system which is essential to maintain the homeostasis.
Although MASP-1 cannot initiate the complement cascade alone,
its activity on HK, fibrinogen and PAR4 can help to mount an
even more powerful immune response.
The major source of BK production in serum is the contact
activation cascade. Factor XII can autoactivate and subsequently
activate prekallikrein to kallikrein by limited proteolysis. Active
plasma kallikrein then digests HK liberating the vasoactive peptide
BK and it also activates additional zymogen factor XII molecules
providing an amplification loop in the kinin cascade. Recently it
was demonstrated that prekallikrein also cleaves HK slowly in a
stoichiometric fashion [7]. Both factor XIIa and plasma kallikrein
can be inhibited by the serpin C1-inhibitor [1]. C1-inhibitor is the
major inhibitor of MASP-2 and it also efficiently inhibits MASP-1
[16,17,38,39]. In the case of HAE when C1-inhibitor is absent or
dysfunctional, and the complement cascade is increasingly
activated [4,40,41], uncontrolled cleavage of HK by MASP-1
may contribute to the elevated BK level. Since MASP-1
autoactivates spontaneously in the absence of inhibitors, it is
possible that this protease cleaves HK, even in the absence of any
contact system activator, contributing to the elevated baseline level
of BK observed in HAE patients [7,42]. On the other hand special
activation of MASP-1 occurring during infection, oxidative stress
or possibly other conditions may initiate HAE attacks. It is
plausible that under these conditions the MASP-1-mediated BK
release may contribute to the worsening of the symptoms, however
further experiments are needed to clarify the exact role of MASP-1
in HAE.
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